Future Perspectives in the Treatment of Neuroblastoma
October 5th 2023Giselle Sholler, MD, and Anurag Agrawal, MD, close their discussion with a look at the future of neuroblastoma treatment, highlighting research being done in areas such as immunotherapies, CAR T-cell therapy, and genomics for more targeted approaches aiming to enhance patient outcomes.
Read More
Anti-GD2 Monoclonal Antibodies in Patients With R/R HRNB: Pivotal Clinical Trials
September 28th 2023Drs Sholler and Agrawal detail recent studies on naxitamab and dinutuximab demonstrating effectiveness in treating recurrent or refractory neuroblastoma, leading to their FDA approvals, and significantly influencing treatment practices.
Read More
Available Treatment Options for Recurrent/Relapsed High-Risk Neuroblastoma (R/R HRNB)
September 28th 2023Key opinion leaders address the treatment of recurrent or relapsed high-risk neuroblastoma, emphasizing the efficacy of antibody therapies naxitamab and dinutuximab, which target neuroblastoma cells, and the significance of post-induction therapy to enhance patient outcomes before transplantation.
Read More
Updated Data From the LEAHRN Study in High-Risk Neuroblastoma
September 21st 2023Experts review updated data from the LEAHRN study presented at the ASCO 2023 Annual Meeting highlighting the long-term toxicities experienced by high-risk neuroblastoma patients, particularly hearing loss, and the potential to modify treatments to reduce these effects.
Read More
Approaches to Diagnosing Neuroblastoma
September 7th 2023Anurag Agrawal, MD, explains his approaches to diagnosing neuroblastoma, including urine markers, imaging, and bone marrow sampling, and emphasizes age and disease dissemination as major prognostic indicators alongside genetic predisposition and treatment response.
Read More